Skip to main content

IMPACT · PURPOSE WITH PROOF

A medicine can exist and still fail to reach the moment it matters.

Medicine can improve and save lives. NEUVIOR’s role is to strengthen the decisions and delivery around it. It does not replace the professionals accountable for care.

We are building infrastructure intended to connect medicines evidence to responsible decisions, visible implementation and learning. The aim is to give more people a better chance of receiving the intended benefit of medicine.

Follow the path to impact See PHARMORIS

Intended contribution · NEUVIOR does not currently claim lives saved or demonstrated clinical outcomes.

PresentPHARMORIS under controlled development
Intended contributionClearer, accountable medicines execution
Human ambitionA system that better serves people

WHY THE GAP MATTERS

The evidence is clear. The system is not.

You can have useful evidence and still lose value when information fragments, ownership blurs or learning arrives too late. These independent sources describe the wider problem. They do not describe NEUVIOR performance.

01Nearly 50%

Medication related harm is a major system problem.

WHO reports that harm associated with medicines and therapeutic options accounts for nearly half of preventable harm in medical care worldwide.

World Health Organization · 2024 Global context, not a NEUVIOR result or a UK specific estimate.
02Fragmented

Medicines information can break across systems and settings.

NHS England says the way medicines information is recorded and shared is often fragmented, creating avoidable risk, duplication and delay for patients and clinicians.

NHS England · Digital Medicines Programme System context, not an endorsement, integration or customer claim.
03Incomplete

Learning is weaker when outcome feedback is not timely.

NHS England’s 2026 quality strategy says inconsistent access to timely, robust outcome data makes it harder to understand where improvement has occurred.

NHS England · Quality strategy · 2026 A national quality challenge, not proof PHARMORIS has closed it.

THE PATH TO IMPACT

We do not jump from software activity to “lives saved”.

The causal chain must stay visible and open to challenge. PHARMORIS can support the operational middle; authorised people, institutions and wider care remain responsible for decisions and outcomes.

  1. 01

    Evidence

    Know what the signal rests on.

    Keep the source, scope, uncertainty and decision context connected so an authorised team can understand what deserves attention.

  2. 02

    Decision

    Keep judgement human and accountable.

    Give the responsible person enough context to continue, narrow, defer or stop, and retain the rationale for review.

  3. 03

    Owned action

    Turn agreement into responsibility.

    Name the owner, next move, dependency and escalation path so a decision does not disappear between teams or systems.

  4. 04

    Implementation

    Keep the decision attached to delivery.

    Make work, blockers, hand offs and closure visible while the institution remains responsible for delivery and governance.

  5. 05

    Human benefit

    Aim for medicine to matter in real life.

    The intended destination is a more reliable medicines system for the person depending on it. That contribution must be evaluated before it is claimed.

Review & learning

Review informed by evidence closes the loop. What progressed, stopped or changed should strengthen the next decision.

PHARMORIS is intended to strengthen the operational middle. Human benefit also depends on professional decisions, institutional delivery, access, wider care and context.

This is a theory of change, not evidence of effect. Outcomes depend on professional judgement, adoption, local governance, data quality, implementation, supply and other systems.

WHO VALUE SHOULD REACH

A better future for every seat in the system.

The same infrastructure creates different value for each person involved. The human benefit sits at the end of the chain, not in the software itself.

  1. 01

    People relying on medicines

    A better chance that a justified medicines opportunity survives the journey from evidence to responsible implementation.

    The intended ultimate beneficiary, not a current PHARMORIS user or a claimed patient outcome.
  2. 02

    Medicines and pharmacy teams

    Clearer context, visible ownership and fewer decisions stranded between analysis, meetings, email and delivery work.

    Professional judgement, clinical responsibility and local policy remain with authorised people.
  3. 03

    Healthcare organisations

    A more reviewable path from a medicines signal to action, escalation, closure and organisational learning.

    Any time, cost, safety, access or workforce benefit must be measured in a governed live evaluation.
  4. 04

    The pharmaceutical ecosystem

    Earlier visibility of implementation friction and a clearer connection between evidence, responsible adoption and what happens next.

    PHARMORIS does not manufacture, prescribe, procure or distribute medicines.

THE COMPANY BEYOND ONE PRODUCT

Understand the opportunity. Develop the response. Build the route to delivery.

A workflow product can strengthen a decision. It cannot formulate a medicine or establish resilient supply. NEUVIOR’s longer term thesis connects those layers in sequence, with each capability earning operating status through evidence, demand, governance and readiness.

Now · current priority

Understand

PHARMORIS is being developed as a governed medicines operations layer between evidence and accountable action.

Explore PHARMORIS
Building next

Develop

Assemble scientific, commercial and partner pathways for justified formulation and medicine development programmes.

See the company direction
Longer term ambition

Deliver

Build or access the quality, regulatory, supply and future manufacturing capability needed for selected medicines.

Read the evidence boundary

This is strategic direction. It is not a claim of current laboratory, manufacturing, regulatory or supply capability.

The purpose is not another dashboard.

It is a better chance for the medicine to matter.

HOW WE WILL EARN THE CLAIM

Measure the work first. Claim human impact only when the evidence reaches it.

Product activity is not adoption. Adoption is not realised value. Realised institutional value is not automatically a clinical outcome. Each layer needs its own baseline, method, evidence owner and limitations.

Proposed evaluation framework. No figures shown here are reported performance.
LayerWhat would be measuredClaim status
01Evidence qualitySource, scope and uncertainty recorded for each governed caseProduct and process measure
02Decision clarityAuthority, rationale, disposition and next review made visibleProduct and process measure
03Execution continuityNamed ownership, blocker age, escalation and governed closureInstitutional evaluation
04LearningImplementation and review completed with the result retainedInstitutional evaluation
05Human outcomeDeployment specific access, experience, safety or health measuresNo claim before independent evidence

OUR COMMITMENT TO TRANSPARENCY

Human purpose. Human responsibility. Evidence before claims.

01

Human authority

Qualified professionals and accountable institutions continue to make consequential decisions.

02

No prescribing

NEUVIOR does not prescribe, dispense, diagnose or replace patient specific advice.

03

Controlled development

PHARMORIS is under controlled development, with deployment and assurance claims gated by current evidence.

04

Outcomes earned

NEUVIOR does not currently claim lives saved, prevented harm, improved patient outcomes or realised savings.

SOURCE LED · REVIEWED 2 AUGUST 2026

Read the evidence behind the ambition.

Classified public record

Trace every publisher record

IDEAS + HUMAN IMPACT

See what must change before a medicine can matter more.

These arguments examine the gap between evidence, decision and delivery. They explain the problem NEUVIOR intends to address; they do not demonstrate lives saved or clinical outcomes.

  1. NEUVIOR Founder ReflectionsNEUVIOR analysis

    After NICE: making medicines access operational

    A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.

    Map the path from recommendation to reliable access
  2. NEUVIOR Founder ReflectionsNEUVIOR analysis

    From invention to adoption: the work between

    Invention creates a possibility. Adoption requires authority, evidence, implementation, review and a reason for people to change what they do.

    See why invention is only the beginning
  3. NEUVIOR InsightsNEUVIOR analysis

    Best value biological medicines are the clearest near term medicines productivity play in the NHS

    If NHS leaders are looking for a near term medicines productivity play with a strong policy tailwind, best value biological medicines should be near the top of the list.

    Explore the near term medicines opportunity
Explore every medicines analysis

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

START WITH ONE REAL BOTTLENECK

Bring the medicines decision that is not moving.

Show us where evidence, ownership, authority or implementation breaks down. We will help map the workflow, identify the missing gates and explain what a bounded evaluation would need to test.

Map your medicines workflow Review the assurance boundary
Do not submit information that identifies a patient, confidential information or sensitive security information through a public form.

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What impact does NEUVIOR aim to create?

NEUVIOR aims to strengthen the systems between medicines evidence, accountable decisions, implementation and learning. Its longer term purpose is to help responsible institutions reduce avoidable friction around medicines and better serve the people who depend on them. These are intended outcomes to be tested. They are not current performance claims.

02How could PHARMORIS ultimately help people who rely on medicines?

The pathway is indirect. PHARMORIS is intended to help authorised teams keep evidence, ownership, decisions, blockers and review connected. If that supports clearer and more reliable institutional execution, people may ultimately experience better access, continuity or communication. Those effects depend on professional decisions and local implementation and must be evaluated rather than inferred from software use.

03Does NEUVIOR claim that it saves lives?

No. Medicines can improve and save lives, and that human purpose motivates NEUVIOR’s work. NEUVIOR has not established that PHARMORIS or any other current activity has saved lives, prevented harm or improved clinical outcomes. A future claim of that kind would require a defined context, baseline, appropriate method, responsible evidence owner and proportionate evaluation. The evaluation may need to be independent or led by an adopter.

04How will NEUVIOR measure impact?

NEUVIOR proposes an evidence ladder. First test source quality, decision clarity, named ownership, blocker age, implementation and review completion. Then evaluate institutional effects against a defined baseline. Access, experience, safety or health outcomes would require measures specific to the operating context and independent evidence before any public claim.

05Does PHARMORIS make clinical or prescribing decisions?

No. PHARMORIS is intended to structure evidence and accountable institutional work around human decisions. It does not prescribe, recommend treatment for an individual, provide advice for an individual patient or replace professional judgement. Authorised professionals and institutions retain their clinical, operational, governance and launch responsibilities.

06What does NEUVIOR aim to build beyond PHARMORIS?

PHARMORIS is the current starting point. NEUVIOR’s longer term thesis connects medicines intelligence with formulation and pharmaceutical development. Future delivery and manufacturing capability would depend on evidence, demand, rights, quality systems and regulatory conditions. Those later layers are strategic direction or capability being built. They are not claims of current laboratory, manufacturing or regulated operations.